Hypoglycemia can be a debilitating effect of insulin therapy. Predictive low glucose suspend (PLGS) systems are under development to help reduce the likelihood and duration of low blood glucose values for people using insulin pump therapy.
Last week, during a poster session at the 2017 Diabetes Technology Meeting in Bethesda, Maryland, we presented results from a Human Factors study validating the safety of the user interface of a PLGS feature as part of the t:slim X2™ Insulin Pump. This study was conducted in the hands of users, with and without insulin pump or CGM experience.
The study was conducted at four independent research centers in the United States and demonstrated a 99 percent success rate among study participants who, after initial training, performed a series of critical tasks using the PLGS system.
Betsy Dokken, PhD, Director of Clinical Affairs and Garret Marin, Sr. Product Manager.
“This study demonstrates that the t:slim X2 System with PLGS requires minimal training and is easy to use, even for people without pump or CGM experience,” said Betsy Dokken, PhD, Director of Clinical Affairs (pictured above) at Tandem Diabetes Care. “We believe that the high success rate and minimal errors observed in this study highlight the importance of human factors research in insulin pump development, particularly with the introduction of automated insulin delivery algorithms.”
Usability is an important consideration for automated insulin delivery systems, and these findings demonstrate that the t:slim X2 System requires minimal training and is easy for participants to use, including those who are pump and/or CGM naïve. In addition, these findings support the effectiveness of online training for the t:slim X2 with PLGS system.
This post includes forward-looking statements relating to the Company’s t:slim X2® Insulin Pump featuring a predictive low glucose suspend feature, including the conclusions from research studies on the ease of use of the pump and the effectiveness of training. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including risks that current and past results of research studies may not be indicative of results of future research studies or of actual user experience. Forward looking statements are also subject to other risks and uncertainties, including those identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update any forward-looking statement in this post.